Business Combination, Aggregate Upfront Payments

No definition available.

Name:	cpix_BusinessCombinationAggregateUpfrontPayments
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Business Combination, Royalties, Range of Payment Over Gross Profits, Percentage

+ References

No definition available.

+ Details

Name:	cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage
Namespace Prefix:	cpix_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Business Combination, Upfront Payment

+ References

No definition available.

+ Details

Name:	cpix_BusinessCombinationUpfrontPayment
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Payments for Contingent Consideration

+ References

No definition available.

+ Details

Name:	cpix_PaymentsforContingentConsideration
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Recognized Gain (Loss) on Contingent Consideration

+ References

No definition available.

+ Details

Name:	cpix_RecognizedGainLossonContingentConsideration
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue Recognition, Potential Upfront Payment Related to Product Sales

+ References

No definition available.

+ Details

Name:	cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_SalesRevenueNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=cpix_OmeclamoxPakMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=cpix_VaprisolMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cpix_AmendedInternationalAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=cpix_PernixTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=cpix_OmeclamoxPakMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=cpix_VaprisolMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Products Added During 2014 and 2013 - Narrative (Details) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 29, 2013	Apr. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Feb. 28, 2014
Business Acquisition [Line Items]
Payments for contingent considerations					$ 1,618,983	$ 0
Net revenues			$ 7,885,048	$ 9,729,047	25,481,563	27,572,459
Upfront payments and milestone payments related to product sales					4,000,000
Omeclamox-Pak
Business Acquisition [Line Items]
Additional upfront payments	$ 4,000,000
Vaprisol
Business Acquisition [Line Items]
Upfront payment							$ 2,000,000
Additional upfront payments							$ 2,000,000
Payments for contingent considerations		$ 1,600,000
Recognized gain on contingent consideration					300,000
Minimum \| Omeclamox-Pak
Business Acquisition [Line Items]
Royalty payments based on percentage over gross profits	15.00%
Maximum \| Omeclamox-Pak
Business Acquisition [Line Items]
Royalty payments based on percentage over gross profits	20.00%
Amended International Agreement \| Pernix Therapeutics
Business Acquisition [Line Items]
Upfront payments and milestone payments related to product sales	$ 4,000,000
Omeclamox-Pak
Business Acquisition [Line Items]
Net revenues			691,120	996,974	2,393,495	3,481,264
Vaprisol
Business Acquisition [Line Items]
Net revenues			$ 670,621	$ 653,070	$ 2,199,645	$ 2,022,835